צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Sunshine Biopharma (SBFM)

Sunshine Biopharma faces a capital deficit and the risks of clinical trial failures. The LTM annual sales volume change on the GURU.Markets chart demonstrates current volatility, where the value of -5.20 shows the most recent figure. Sunshine Biopharma develops innovative anti-cancer agents that target pathogen mechanisms and implements robotic molecule screening and automated data array processing.
פילוחי נתונים אנליטיים מרוכזים עבור Sunshine Biopharma, Inc. (SBFM)

This indicator measures the relative change in revenue over a rolling year, allowing for an assessment of the current business expansion rate without seasonal distortions. For Sunshine Biopharma (SBFM), the TTM year-over-year sales growth rate reflects the current resilience of the generic segment, while the expected future launch of innovative drugs could radically alter the trajectory of this chart.